Type to search

Vaxzevria Approved in the EU as Third Dose Booster Against COVID-19 | Pharmtech Focus
Farxiga Met Primary Endpoint in DELIVER Phase III Trial, Reducing Risk of Cardiovascular Death or Worsening Heart Failure in Patients with Preserved Ejection Fraction | Pharmtech Focus
BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure | Pharmtech Focus